KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Liabilities and Shareholders Equity (2018 - 2025)

Takeda Pharmaceutical (TAK) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $113.4 billion in Q1 2022.

  • For Q1 2022, Liabilities and Shareholders Equity fell 7.04% year-over-year to $113.4 billion; the TTM value through Mar 2025 reached $113.4 billion, down 51.83%, while the annual FY2022 figure was $117.4 billion, 3.63% down from the prior year.
  • Liabilities and Shareholders Equity reached $113.4 billion in Q1 2022 per TAK's latest filing, down from $122.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $125.3 billion in Q1 2019 and bottomed at $113.4 billion in Q1 2022.
  • Average Liabilities and Shareholders Equity over 3 years is $120.2 billion, with a median of $122.0 billion recorded in 2021.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 7.04% in 2022, down 7.04% in 2022.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $125.3 billion in 2019, then decreased by 2.63% to $122.0 billion in 2021, then fell by 7.04% to $113.4 billion in 2022.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $113.4 billion in Q1 2022, $122.0 billion in Q1 2021, and $125.3 billion in Q1 2019.